Skip to main content
Premium Trial:

Request an Annual Quote

Cardinal Health to Distribute GenePOC Instrument, Assays in US

NEW YORK (GenomeWeb) – Canadian molecular diagnostics firm GenePOC said today that Cardinal Health will be the exclusive distributor of its revogene instrument and associated assays in the US.

The revogene instrument is a portable, qPCR-based molecular diagnostics instrument that runs point-of-care tests. Earlier this month, the US Food and Drug Administration cleared for marketing the instrument along with the GenePOC GBS LB assay for detecting Group B streptococcus.

"We are confident that this new partnership will support us in making a real difference in the diagnosis of infectious diseases by being closer to the patient," GenePOC CEO Patrice Allibert said in a statement. "We further believe this distribution agreement will pave the way for GenePOC to become a key molecular testing player in the mid-size molecular lab, the satellite lab, and all the way into the point-of-care market."

GenePOC is based in Québec and is part of the Debiopharm Group of companies.

The Scan

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.

Topical Compound to Block EGFR Inhibitors May Ease Skin Toxicities, Study Finds

A topical treatment described in Science Translational Medicine may limit skin toxicities seen with EGFR inhibitor therapy.

Dozen Genetic Loci Linked to Preeclampsia Risk in New GWAS

An analysis of genome-wide association study data in JAMA Cardiology finds genetic loci linked to preeclampsia that have ties to blood pressure.

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.